Shorouk Dannoon, Saud Alenezi, Abdelhamid Elgazzar
{"title":"Evaluation of heterotopic ossification maturity using SPECT/CT and PET/CT in preclinical model","authors":"Shorouk Dannoon, Saud Alenezi, Abdelhamid Elgazzar","doi":"10.1016/j.nucmedbio.2024.108950","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Heterotopic ossification (HO) is the formation of bone within soft tissue where bone normally does not exist. In general, it is characterized by highly active tissue with high bone turnover and rapid bone formation. It is of an utmost importance to precisely identify and accurately diagnose the maturity of HO as early surgical intervention may result in its recurrence. The objective of this work is the experimental evaluation of HO maturity stage using advanced noninvasive nuclear medicine techniques. The use of PET radiopharmaceuticals may result in a more specific diagnosis between the phases due to their higher sensitivity and better resolution compared to bone scan.</p></div><div><h3>Method</h3><p>8-week-old Balb/c male mice underwent dual injury procedure, tenotomy and concurrent burn injury on the left side, to induce HO. The progression of HO was monitored by SPECT/CT and PET/CT weekly imaging with <sup>99m</sup>Tc-MDP, [<sup>18</sup>F]NaF and [<sup>18</sup>F]FDG for up to 16 weeks.</p></div><div><h3>Results</h3><p>There was a statistically significant increase of [<sup>18</sup>F]FDG uptake from week 1 to 2 and from week 2 to 6 with <em>p</em> values of 0.01 and 0.005; respectively, while there was a statistically significant decrease from week 7 to 14 with a <em>p</em> value of 0.008. There was a statistically significant increase of [<sup>18</sup>F]NaF uptake from week 2 to 5 and statistically significant decrease between weeks 7 and 14 with <em>p</em> values of 0.016 and 0.003; respectively. As for <sup>99m</sup>Tc-MDP, the increase in the uptake from week 1 to 2 and from week 2 to 5 were not statistically significant with <em>p</em> values of 0.15 and 0.19; respectively. The decrease of uptake between week 7 and 14 was not statistically significant with a <em>p</em> value of 0.08.</p></div><div><h3>Conclusion</h3><p>Based on these findings, the use of noninvasive nuclear imaging modalities may assist in distinguishing between the immature and mature phases. The uptake of mainly [<sup>18</sup>F]FDG may indicate the early inflammatory phase, while the uptake of both [<sup>18</sup>F]FGD and [<sup>18</sup>F]NaF may suggest the immature phase, and an uptake of mainly [<sup>18</sup>F]NaF may indicate the maturity phase of HO.</p></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"138 ","pages":"Article 108950"},"PeriodicalIF":3.6000,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear medicine and biology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0969805124000763","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Heterotopic ossification (HO) is the formation of bone within soft tissue where bone normally does not exist. In general, it is characterized by highly active tissue with high bone turnover and rapid bone formation. It is of an utmost importance to precisely identify and accurately diagnose the maturity of HO as early surgical intervention may result in its recurrence. The objective of this work is the experimental evaluation of HO maturity stage using advanced noninvasive nuclear medicine techniques. The use of PET radiopharmaceuticals may result in a more specific diagnosis between the phases due to their higher sensitivity and better resolution compared to bone scan.
Method
8-week-old Balb/c male mice underwent dual injury procedure, tenotomy and concurrent burn injury on the left side, to induce HO. The progression of HO was monitored by SPECT/CT and PET/CT weekly imaging with 99mTc-MDP, [18F]NaF and [18F]FDG for up to 16 weeks.
Results
There was a statistically significant increase of [18F]FDG uptake from week 1 to 2 and from week 2 to 6 with p values of 0.01 and 0.005; respectively, while there was a statistically significant decrease from week 7 to 14 with a p value of 0.008. There was a statistically significant increase of [18F]NaF uptake from week 2 to 5 and statistically significant decrease between weeks 7 and 14 with p values of 0.016 and 0.003; respectively. As for 99mTc-MDP, the increase in the uptake from week 1 to 2 and from week 2 to 5 were not statistically significant with p values of 0.15 and 0.19; respectively. The decrease of uptake between week 7 and 14 was not statistically significant with a p value of 0.08.
Conclusion
Based on these findings, the use of noninvasive nuclear imaging modalities may assist in distinguishing between the immature and mature phases. The uptake of mainly [18F]FDG may indicate the early inflammatory phase, while the uptake of both [18F]FGD and [18F]NaF may suggest the immature phase, and an uptake of mainly [18F]NaF may indicate the maturity phase of HO.
期刊介绍：
Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized.
These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field.
Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
